Clinical Factors Help Define Use of Radionuclide Therapy in Neuroendocrine Tumors

Tony Berberabe, MPH @OncBiz_Wiz
Published: Friday, Jul 05, 2019
Thorvardur Halfdanarson, MD

Thorvardur Halfdanarson, MDe

Radiopharmaceuticals have been integrated into the treatment paradigm for patients with neuroendocrine tumors (NETs), yet there are nuances in the clinical scenarios in which they are most effective, according to Thorvardur Halfdanarson, MD.

Table. NETTER-1 Population Characteristics3

Table. NETTER-1 Population Characteristics
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication